Gland Pharma Limited — PPTs, 15-05-2026: Investor Presentation

Gland Pharma delivered a strong Q4 FY26, with revenue up 22% YoY to ₹1,742.8 Cr and full-year revenue hitting ₹6,430.7 Cr (up 14% YoY). Adjusted PAT soared 97% in Q4 to ₹366.7 Cr, reaching ₹1,045.5 Cr for FY26 (up 50% YoY). Consolidated Adj. EBITDA margin improved to 30% in Q4.

Growth drivers include new product launches (5 in US this quarter, 31 for FY26), especially complex injectables and RTU bags, and strategic capacity expansion in Europe. Cenexi's Fontenay facility is set to become Europe's largest ampoule manufacturer by 2027.

Recent updates: 8 ANDAs filed and 11 approved in Q4 (24 filed, 28 approved for FY26). A new CDMO contract for oncology injectables and a hormonal PFS contract at Braine were secured. Management is keen on expanding the complex pipeline and co-development. The board has proposed a final dividend of ₹20 per share for FY26, pending approval.

Capital expenditure for FY26 was ₹493.8 Cr, with strong cash flow from operations at ₹1,031.4 Cr, and net cash of ₹3,115.7 Cr.